It is the post hoc analysis of phase 2 data some time ago...... they didnt just whip out a new phase 2 whilst we werent looking - it is for this conference.
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-19
-
- There are more pages in this discussion • 125 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5951 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 133644 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |